Blog Post
Marianne_BCNA
8 years agoMember
Hi @iserbrown,
That's correct - the Pharmaceutical Benefits Advisory Committee (PBAC) sat on the 20th of March but we won't know the outcome until the 20th April. If the PBAC recommends that the drugs be listed, it then has to go to cabinet for approval; hence all the letters you have all been writing to your local members.
We'll keep you posted!
That's correct - the Pharmaceutical Benefits Advisory Committee (PBAC) sat on the 20th of March but we won't know the outcome until the 20th April. If the PBAC recommends that the drugs be listed, it then has to go to cabinet for approval; hence all the letters you have all been writing to your local members.
We'll keep you posted!
Related Content
The Oncotype DX test is highly effective at identifying the 70% of patients who can safely avoid chemotherapy and the 30% for whom chemotherapy is optimal. A sample of a tumour is sent to the US wher...
2 months ago130Views
0likes
4Comments
The drug Kisqali (ribociclib), which was previously available for advanced cases, is now being subsidised for a broader group of patients, specifically those with early-stage, hormone receptor-positi...
2 months ago78Views
3likes
1Comment
Good morning, Sharing my experience with Ribociclib for early stage BC. (Diagnosis Nov 23, Stage 2B, Grade 2, WLE, Rads and then Letrozole / Ribo / Zometa / monthly zoladex) I had been on the Ribo...
2 years ago105Views
0likes
2Comments
That didn’t take long to have all the side effects back. i sure enjoyed the break maybe too much did heaps and had lots happening Just finished my 21 days and it's been like i didn’t get a break at al...
3 years ago691Views
0likes
30Comments
Please excuse my spelling guys, the names of these drugs do my head in! I have a friend who is currently taking this medication as a last attempt at slowing the progression of her metastatic cancer, s...
7 years ago301Views
0likes
10Comments